Abstract:Objective There are numerous reasons for short stature, including mutations in osteochondral development genes. ACAN, one such osteochondral development gene in which heterozygous mutations can cause short stature, has attracted attention from researchers in recent years. Therefore, we analyzed six cases of short stature with heterozygous ACAN mutations and performed a literature review. Methods Clinical information and blood samples from 6 probands and their family members were collected after consent forms were signed. Gene mutations in the probands were detected by whole-exome sequencing. Then, we searched the literature, performed statistical analyses, and summarized the characteristics of all reported cases. Results We identified six novel mutations in ACAN: c.1411C>T, c.1817C>A, c.1762C>T, c.2266G>C, c.7469G>A, and c.1733-1G>A. In the literature, more than 200 affected individuals have been diagnosed genetically with a similar condition (height standard deviation score [SDS] -3.14 ± 1.15). Among affected individuals receiving growth-promoting treatment, their height before and after treatment was SDS -2.92 ± 1.07 versus SDS -2.14 ± 1.23 (P<.001). As of July 1, 2019, a total of 57 heterozygous ACAN mutations causing nonsyndromic short stature had been reported, including the six novel mutations found in our study. Approximately half of these mutations can lead to protein truncation. Conclusions This study used clinical and genetic means to examine the relationship between the ACAN gene and short stature. To some extent, clear diagnosis is difficult, since most of these affected individuals’ characteristics are not prominent. Growth-promoting therapies may be beneficial for increasing the height of affected patients. Abbreviations: AI = aromatase inhibitor; ECM = extracellular matrix; GnRHa = gonadotropin-releasing hormone analogue; IQR = interquartile range; MIM = Mendelian Inheritance in Man; PGHD = partial growth hormone deficiency; rhGH = recombinant human growth hormone; SDS = standard deviation score; SGA = small for gestational age; SGHD = severe growth hormone deficiency

Meclozine and growth hormone ameliorate bone length and quality in experimental models of achondroplasia

Clinical dosage of meclozine promotes longitudinal bone growth, bone volume, and trabecular bone quality in transgenic mice with achondroplasia

Low–dose infigratinib increases bone growth and corrects growth plate abnormalities in an achondroplasia mouse model

Advances in the mechanism and therapies of achondroplasia

Evaluation of FGFR inhibitor ASP5878 as a drug candidate for achondroplasia

Clinical outcomes and medical management of achondroplasia in Japanese children: A retrospective medical record review of clinical data

Advantages and Disadvantages of Different Treatment Methods in Achondroplasia: A Review

Achondroplasia: aligning mouse model with human clinical studies shows crucial importance of immediate postnatal start of the therapy

Intermittent PTH (1-34) injection rescues the retarded skeletal development and postnatal lethality of mice mimicking human achondroplasia and thanatophoric dysplasia.

Combination treatment with growth hormone and zoledronic acid in a mouse model of Osteogenesis imperfecta

New treatments for children with achondroplasia

Peptides From Euphausia Superba Promote Longitudinal Bone Growth By Accelerating Growth Plate Chondrocyte Proliferation And Hypertrophy

Defective Lysosomal Targeting of Activated Fibroblast Growth Factor Receptor 3 in Achondroplasia.

Growth-Promoting Therapies May Be Useful in Short Stature Patients with Nonspecific Skeletal Abnormalities Caused by Acan Heterozygous Mutations: Six Chinese Cases and Literature Review

Achondroplasia current concept of orthopaedic management

Mouse Models Orthologous to FGFR3-related Skeletal Dysplasias.

Identification of short stature caused by SHOX defects and therapeutic effect of recombinant human growth hormone

A Lys644Glu Substitution in Fibroblast Growth Factor Receptor 3 (FGFR3) Causes Dwarfism in Mice by Activation of STATs and Ink4 Cell Cycle Inhibitors.

Retinoid-impregnated nanoparticles enable control of bone growth by site-specific modulation of endochondral ossification in mice

A Ser(365)-->Cys Mutation of Fibroblast Growth Factor Receptor 3 in Mouse Downregulates Ihh/PTHrP Signals and Causes Severe Achondroplasia.

Role of Cholesterol in the Regulation of Growth Plate Chondrogenesis and Longitudinal Bone Growth*